Takura has acquired all shares in clinical stage immuno-oncology company Polybiocept GmbH (PBC). Takura was already a minority owner in the company which owns a patent portfolio for TIL (tumor infiltrating lymphocytes) therapy. Immunotherapy is one of the fastest growing segments in the pharmaceutical industry and has the potential to revolutionize cancer care. PBC has a collaboration with Krankenhaus Nordwest (KHNW) in Frankfurt where 16 patients with solid cancers have been treated with PBC’s technology under hospital exemption. The company has now started to plan for a phase I clinical trial.
Takura acquires Polybiocept GmbH
14 juli, 2020/